Aclaris Therapeutics, Inc. (ACRS) Stock Price & Analysis

Aclaris Therapeutics, Inc. (ACRS) fell 1.38% to USD 4.3 as of June 10, 2026 at 03:10 UTC, according to Nexqual real-time market data.

ACRS last closed at USD 4.36; the session ranged USD 4.22–4.47 on volume of 1,000,446 shares. Market capitalization is $600.55M, with a 52-week range of USD 1.34–5.15 (NMS). Source: Nexqual, June 10, 2026 at 03:10 UTC.

Key Statistics (as of June 10, 2026 at 03:10 UTC)

Technical Analysis (ACRS)

Nexqual's technical model rates ACRS "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:10 UTC.

Analyst Ratings (ACRS)

Wall Street analysts rate ACRS "Strong Buy" based on 10 analysts, with a mean price target of USD 10 (range USD 4–16), per Nexqual as of June 10, 2026 at 03:10 UTC.

Earnings (ACRS)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 03:10 UTC.

Financials & Fundamentals (ACRS)

Source: Nexqual, June 10, 2026 at 03:10 UTC.

Financial Health Score (ACRS)

Nexqual rates Aclaris Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:10 UTC.

Ownership (ACRS)

Source: Nexqual, June 10, 2026 at 03:10 UTC.

Leadership (ACRS)

Aclaris Therapeutics, Inc. is led by Neal S. Walker D.O. (age 55), Co-Founder, CEO & Chairman, per Nexqual as of June 10, 2026 at 03:10 UTC.

Major Backers & Investors (ACRS)

Notable institutional backers of Aclaris Therapeutics, Inc. include BML Capital Management, LLC, Deep Track Capital, Lp, RA Capital Management, L.P., according to Nexqual as of June 10, 2026 at 03:10 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 03:10 UTC.

From Aclaris Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency.
• We expect to file an IND application for ATI-9494 in the second half of 2026. ​ Discovery and Preclinical Programs ​ We conduct small molecule drug discovery through KINect, our proprietary drug discovery platform.
• We aim to take advantage of all of the intellectual property rights that are available to us and believe that this comprehensive approach will provide us with proprietary positions for our product candidates, where available. ​ We also protect our proprietary information by requiring our employees, consultants, contractors and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective employment or engagement.
• We are seeking to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our novel product candidates. ​ Our Approach ​ We are dedicated to developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options .

Partnerships

• In addition, we also require confidentiality or service agreements from third parties that receive our confidential information or materials. ​ Acquisition and License Agreements ​ Exclusive License Agreement with Biosion ​ In November 2024, we entered into an exclusive license agreement (the "Biosion Agreement") with Biosion, pursuant to which we received exclusive rights to develop, manufacture and commercialize bosakitug and ATI-052 worldwide, excluding Greater China.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:10 UTC. This page is informational and not investment advice.